泽璟制药关于自愿披露注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗（依托泊苷/卡铂）联用获得药物临床试验批准通知书的公告
仅供参考，请查阅当日公告全文。
公告全文参考链接:
View Attachment
仅供参考，请查阅当日公告全文。
公告全文参考链接:
View Attachment
泽璟制药关于自愿披露注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗（依托泊苷/卡铂）联用获得药物临床试验批准通知书的公告
Filed with SSE ·
On 6ix: 6ix.com/news/zg006pd-1pd-l1
6ix hasn’t read this filing yet.
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of FDA Orphan Drug Designation for Injectable ZG006 in the Treatment of Neuroendocrine Cancer
- Announcement on Resolutions of the 3rd Meeting of the 4th Board of Directors
- Announcement on Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Combination of ZG006 for Injection with Etoposide and Cisplatin
- Report for Q3 2025
- Announcement on Convening the Q3 2025 Performance Briefing
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy Designation
- Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 Presented at the 2025 European Society for Medical Oncology Asian Annual Meeting (ESMOAsia)
- Announcement on Voluntary Disclosure of Inclusion of Gecacitinib Hydrochloride Tablets in the 2025 National Medical Insurance Drug Catalog
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Conclusion of a Global Strategic Cooperation and License Option Agreement with AbbVie Regarding the Development and Commercialization Rights of ZG006
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals